All Pharma News
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
PRESS RELEASE
24 Apr 2024
Share Share
Incyte Biologic Zynyz (retifanlimab-dlwr) Receives Approval in the U.S.

Incyte Biologic Zynyz (retifanlimab-dlwr) Receives Approval in the U.S.

FDA
22 Apr 2024
Share Share
CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China

CMS & Incyte collaborate to develop vitiligo drug Povorcitinib in China
BIOSPECTRUM ASIA
04 Apr 2024
Share Share
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BUSINESSWIRE
29 Mar 2024
Share Share
Ironwood spies new frontier for $1B drug in exploratory trial

Ironwood spies new frontier for $1B drug in exploratory trial
FIERCE BIOTECH
29 Mar 2024
Share Share
Incyte`s oral Dupixent rival hits in midphase skin disease trial

Incyte`s oral Dupixent rival hits in midphase skin disease trial
FIERCE BIOTECH
12 Mar 2024
Share Share
Incyte`s Opzelura scores in hidradenitis suppurativa study

Incyte`s Opzelura scores in hidradenitis suppurativa study
Zoey Becker FIERCE PHARMA
11 Mar 2024
Share Share
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream
BUSINESSWIRE
10 Mar 2024
Share Share
Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib

Incyte Presents Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib
BUSINESSWIRE
10 Mar 2024
Share Share
New Data from Incyte’s Growing Dermatology Portfolio to be Presented

New Data from Incyte’s Growing Dermatology Portfolio to be Presented
BUSINESSWIRE
04 Mar 2024
Share Share